🧾 What This Document Is

This is a 6-K form, which is a report foreign companies like Telix (an Australian company listed on the US Nasdaq) file with the SEC to share major news with American investors. Think of it as a formal, required announcement to the US market.

👉 In simple terms: Telix is telling the US market, "We're adding two experienced experts to our board of directors."

🏢 What The Company Does

In simple terms, Telix Pharmaceuticals is a biotech company that creates special drugs called radiopharmaceuticals. These are like "smart bombs" used in cancer imaging and treatment—they deliver radiation directly to cancer cells while sparing healthy tissue.

The company is global, headquartered in Australia but with major operations in the US and Europe. Being listed on both the Australian (ASX) and US (NASDAQ) stock exchanges means it needs strong governance that meets high international standards.

🤝 The New Directors

This announcement is all about adding two new Non-Executive Directors (NEDs) to the board. These are independent advisors who provide oversight and strategic guidance.

• Maria Rivas, MD: She's a heavyweight from the big pharma world, most recently as Chief Medical Officer at Pfizer. She brings 25+ years of experience in getting drugs through late-stage trials and launching them commercially, especially in oncology and rare diseases—which is exactly Telix's focus.
• William (Bill) Jellison: He's a financial and governance guru, most recently the CFO of medical device giant Stryker. He brings over 30 years of experience in corporate finance, audits, and mergers & acquisitions for large, regulated companies.

👉 Why they matter: Their hiring signals Telix is serious about maturing as a global public company. Dr. Rivas adds deep drug development know-how, while Mr. Jellison adds top-tier financial oversight.

🚀 Why This Move Is Key

The company explicitly says these appointments are part of a Board expansion and succession planning. This is a proactive move, not a reaction to a problem.

• It follows the recent addition of another director, David Gill.
• The Interim Chair, Dr. Mark Nelson, states this is "well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company."

👉 What this signals: Telix is transitioning from a development-focused biotech to a commercially operating pharmaceutical company. They're building a board that has the specific experience to guide that next, more complex phase.

⚖️ Big Picture Strengths & Risks

👍 Strengths:

• Expertise Upgrade: The new directors fill potential experience gaps in late-stage development (Rivas) and complex financial oversight (Jellison).
• Governance Credibility: Adding directors with backgrounds at Pfizer, Stryker, and Medtronic boosts the company's credibility with large institutional investors.
• Strategic Alignment: The hires directly support the company's stated goal of being a global commercial-stage player.

⚠️ Risks to Consider:

• Integration Challenge: New directors take time to get up to speed on a company's unique science and strategy.
• Commercial Execution: While the board is strengthening, the key risk for Telix remains executing its drug launches and commercial strategy successfully.
• Market Focus: The emphasis on US public company governance is vital but also adds layers of regulatory cost and complexity.

📅 Key Dates & Contacts

• Effective Date: The appointments are effective May 11, 2026 (subject to receiving Australian Director IDs).
• Investor Relations:
  • Global: Kyahn Williamson - [email protected]
  • Australia: Charlene Jaw - [email protected]
  • U.S.: Annie Kasparian - [email protected]
• Media Contact: Eliza Schleifstein - 917.763.8106 (Mobile) / [email protected]

🧠 The Analogy

Telix is like a promising tech startup that has just built an amazing product (its cancer drugs) and is now hiring seasoned executives from Apple and Goldman Sachs to lead it through its IPO and global expansion. They're shifting from a "lab" mentality to a "Fortune 500" mentality.

🧩 Final Takeaway

Telix is strategically strengthening its board with two powerhouse directors from Pfizer and Stryker to provide the expert oversight needed as it transforms from a development-stage biotech into a fully commercial, global pharmaceutical company.